EURO Stock Overview
Euro-Med Laboratories Phil., Inc. manufactures and sells various pharmaceutical products in the Philippines and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
+ 1 more risk
Euro-Med Laboratories Phil., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₱0.78 |
| 52 Week High | ₱0.88 |
| 52 Week Low | ₱0.70 |
| Beta | 0.52 |
| 1 Month Change | -1.27% |
| 3 Month Change | -2.50% |
| 1 Year Change | -8.24% |
| 3 Year Change | -60.20% |
| 5 Year Change | -53.85% |
| Change since IPO | 28.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| EURO | PH Pharmaceuticals | PH Market | |
|---|---|---|---|
| 7D | 5.4% | 2.0% | 0.3% |
| 1Y | -8.2% | 0.6% | -1.4% |
Return vs Industry: EURO underperformed the PH Pharmaceuticals industry which returned 0.6% over the past year.
Return vs Market: EURO underperformed the PH Market which returned -1.4% over the past year.
Price Volatility
| EURO volatility | |
|---|---|
| EURO Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PH Market | 12.5% |
| 10% least volatile stocks in PH Market | 2.7% |
Stable Share Price: EURO has not had significant price volatility in the past 3 months.
Volatility Over Time: EURO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of PH stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,604 | Georgiana Evidente | www.euromedlab.net |
Euro-Med Laboratories Phil., Inc. manufactures and sells various pharmaceutical products in the Philippines and internationally. It manufactures and distributes large and small volume parenterals that are used as solvents for other drugs; sterile water for injection; and other solutions for ophthalmic, inhalation, irrigation, and dialysis. The company also offers specialty fluids comprising dialysis solutions for the treatment of acute or chronic renal failure; hemodialysis solution, a concentrated solution of electrolytes in water for injection; irrigation solutions, which are sterile solutions that are used to bathe and flush open wounds or body cavities; mannitol injection, an osmotic diuretic, which promotes the excretion of water; Dextran 70, a fluid to expand blood volume; and Metronidazole for infections of gum and dental cavities, and pressure sores, as well as pelvic area, brain and lung, bones, gastrointestinal, genital tract, and blood infections.
Euro-Med Laboratories Phil., Inc. Fundamentals Summary
| EURO fundamental statistics | |
|---|---|
| Market cap | ₱3.00b |
| Earnings (TTM) | ₱289.95m |
| Revenue (TTM) | ₱5.26b |
11.1x
P/E Ratio0.6x
P/S RatioIs EURO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EURO income statement (TTM) | |
|---|---|
| Revenue | ₱5.26b |
| Cost of Revenue | ₱3.37b |
| Gross Profit | ₱1.89b |
| Other Expenses | ₱1.60b |
| Earnings | ₱289.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.071 |
| Gross Margin | 35.98% |
| Net Profit Margin | 5.51% |
| Debt/Equity Ratio | 66.6% |
How did EURO perform over the long term?
See historical performance and comparison